Xlife Sciences AGXSWX:XLS -11.06%50 PB Ratio is 0.42 as of Jun. 25, 2026, which is 40% below its 10-year median of 0.70. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 1,233 Biotechnology companies, Xlife Sciences AG ranks better than 95.7% on this metric.
Xlife Sciences AG stock PB Ratio (=0.51) is close to 1-year high of 0.52.
The historical rank and industry rank for Xlife Sciences AG's PB Ratio or its related term are showing as below:
XSWX:XLS'
s PB Ratio Range Over the Past 10 Years
Min: 0.33 Med: 0.7 Max: 1.25
Current: 0.43
During the past 8 years, Xlife Sciences AG's highest PB Ratio was 1.25. The lowest was 0.33. And the median was 0.70.
XSWX:XLS's PB Ratio is ranked better than 95.7% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs XSWX:XLS: 0.43
During the past 12 months, Xlife Sciences AG's average Book Value Per Share Growth Rate was -6.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.30% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Xlife Sciences AG was 21.40% per year. The lowest was 3.70% per year. And the median was 15.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Xlife Sciences AG PB Ratio Related Terms
Xlife Sciences AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xlife Sciences AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Xlife Sciences AG (XSWX:XLS) has a PB Ratio of 0.42 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xlife Sciences AG and its competitors. This is 40% below median its historical median of 0.70. Over the past decade, Xlife Sciences AG's PB Ratio has ranged from 0.33 to 1.25. According to the industry distribution chart, Xlife Sciences AG ranks #53 out of 1233 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Xlife Sciences AG's PB Ratio too high?
Xlife Sciences AG's current PB Ratio of 0.42 is 40% below median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.25. The Biotechnology industry median PB Ratio is 2.80. Xlife Sciences AG's value of 0.42 is 85% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #53 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #53 out of 1233 companies for PB Ratio. This places Xlife Sciences AG in the top 4% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Xlife Sciences AG's value of 0.42 is 85% below this benchmark. Historically, Xlife Sciences AG's own PB Ratio has ranged from 0.33 to 1.25 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 2.80, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current PB Ratio of 0.42 is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current PB Ratio is 0.42, which is 40% below median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current PB Ratio is 0.42, which is 40% below median its 10-year median of 0.70 and 85% below the Biotechnology industry median of 2.80. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current PB Ratio is 0.42 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
PB Ratio: 0.42 (40% below median its 10-year median of 0.70)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
Industry Position: 85% below the Biotechnology median (#53 of 1233)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
